National Institutes of Health to Grant Exclusive License to Immunova Therapeutics for Cancer Treatment

Summary

The National Institutes of Health is issuing a notice of intent to grant a start-up exclusive commercial license to Immunova Therapeutics, Inc. to develop and use patent applications related to cancer treatment, specifically MHC Class II Restricted T Cell Epitopes from the cancer antigen NY ESO-1.